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Abstract
There is growing interest in HIV-specific antibody-dependent cellular cytotoxicity (ADCC) as an effective immune response
to prevent or control HIV infection. ADCC relies on innate immune effector cells, particularly NK cells, to mediate control of
virus-infected cells. The activation of NK cells (i.e., expression of cytokines and/or degranulation) by ADCC antibodies in
serum is likely subject to the influence of other factors that are also present. We observed that the HIV-specific ADCC
antibodies, within serum samples from a panel of HIV-infected individuals induced divergent activation profiles of NK cells
from the same donor. Some serum samples primarily induced NK cell cytokine expression (i.e., IFNc), some primarily
initiated NK cell expression of a degranulation marker (CD107a) and others initiated a similar magnitude of responses across
both effector functions. We therefore evaluated a number of HIV-relevant soluble factors for their influence on the
activation of NK cells by HIV-specific ADCC antibodies. Key findings were that the cytokines IL-15 and IL-10 consistently
enhanced the ability of NK cells to respond to HIV-specific ADCC antibodies. Furthermore, IL-15 was demonstrated to
potently activate ‘‘educated’’ KIR3DL1
+ NK cells from individuals carrying its HLA-Bw4 ligand. The cytokine was also
demonstrated to activate ‘‘uneducated’’ KIR3DL1
+ NK cells from HLA-Bw6 homozygotes, but to a lesser extent. Our results
show that cytokines influence the ability of NK cells to respond to ADCC antibodies in vitro. Manipulating the
immunological environment to enhance the potency of NK cell-mediated HIV-specific ADCC effector functions could be
a promising immunotherapy or vaccine strategy.
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Introduction
The development of a safe and effective HIV vaccine is urgently
needed. Traditional HIV vaccine constructs have focused on the
induction of broadly neutralizing antibodies (BnAbs) and cytotoxic
T-lymphocytes (CTL) [1]. However, several lines of evidence
suggest that non-neutralizing HIV-specific antibodies could play
an important role in preventing or controlling HIV infection.
These antibodies can bind to infected cells and recruit innate
immune effector cells, such as natural killer (NK) cells, to lyse
infected cells through antibody-dependent cellular cytotoxicity
(ADCC). A recent HIV vaccine efficacy trial based on a recombi-
nant Canarypox virus prime and envelope protein boost showed
partial protection from HIV infection, despite inducing only
narrow neutralizing antibody responses and very modest CTL
responses [2]. High levels of HIV-specific ADCC-competent
antibodies were induced by this regimen, suggesting such
responses may play a role in protective immunity [3,4]. This idea
is supported by elegant passive transfer experiments in Rhesus
macaques, which demonstrate decreased effectiveness of BnAbs no
longer capable of eliciting antibody constant region (Fc)-dependent
ADCC responses [5]. Furthermore, ADCC responses have been
associated with protective outcomes against immunodeficiency
viruses [6,7], in particular this has been observed in highly exposed
seronegative intravenous drug users, HIV-infected elite controllers
and vaccinated Rhesus macaques [8–10].
The potential effectiveness of infection-induced HIV-specific
ADCC responses suggests that attempts to improve or modulate
these responses could provide a therapeutic benefit or assist in
protective immunity. Understanding the best mechanisms to
present ADCC epitopes for immune recognition, or to improve
the potency with which they activate NK cells, may be important
for improving ADCC-based therapeutic or preventative strategies.
Recent research has highlighted the importance of antibody
specificity and the glycosylation of antibody Fc regions for driving
efficient ADCC responses [11,12]. It has also been demonstrated
that NK cells are more likely to mediate ADCC if NK cell function
was conferred through the interaction of inhibitory killer cell
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patibility complex (MHC) class I (or HLA-I) ligands during the
process of NK cell education [13–15]. Furthermore, soluble
factors within plasma, such as cytokines, have been demonstrated
to effect NK cell responsiveness [16] and have been associated
with the rate of disease progression [17], potentially due to
a synergistic effect on NK cell mediated anti-HIV ADCC.
Alterations in production and plasma/sera levels of cytokines
during HIV infection are extensive. Investigators have reported
increases in the ability of peripheral blood mononuclear cells
(PBMC) to produce IL-4 [18] and IL-10 [19], while increased
levels of soluble IL-10 [20], IL-7 [21], GM-CSF [22], and TNFa
[23] have been observed in the plasma of infected individuals.
Furthermore, reductions in the production of IL-12 and IL-15
have been reported in HIV-infected individuals [24,25]. The
presence of other soluble plasma factors has also been noted to be
enhanced during HIV infection. Most notably, LPS levels are
increased in HIV-infected individuals [26], and have been
correlated with the level of immune activation and disease
progression [27]. The influence of cytokines on NK cell-mediated
HIV-specific ADCC has not been thoroughly studied. Such
studies could ultimately lead to understanding how best to
influence the immune environment to obtain optimal ADCC
levels during therapeutic and/or prophylactic interventions.
NK cells are exquisitely sensitive to exogenous cytokines, which
can increase or decrease multiple effector functions [16]. Most
anti-HIV ADCC assays utilize whole serum or plasma that
contains not only the antibody of interest but also variable levels of
a suite of biologically activate cytokines. Indeed, chronic viral
infections, such as HIV, substantially perturb plasma cytokine
levels, which could plausibly influence the effectiveness of ADCC
responses in vivo. Upon activation NK cells mediate a variety of
effector functions, including the release of cytokines and
chemokines, and degranulation to kill neighboring virus-infected
cells. We hypothesized that exposure of NK cells to different
exogenous cytokines prior to activation would differentially alter
the effector functions mediated by activated NK cells. Further-
more, as educated NK cells are conferred with higher functional
potential [28], we hypothesized that NK cells educated through
KIR3DL1/HLA-Bw4 interactions would be more susceptible to
the effects of exogenous cytokines than KIR3DL1
+ NK cells from
HLA-Bw6 homozygous individuals. We used a recently developed
flow-based ADCC assay that measures NK cell activation (IFNc
synthesis and CD107a degranulation marker expression) to
evaluate these hypotheses [29,30]. Whole blood from HIV-
uninfected healthy controls was incubated with HIV antigens
and ADCC-competent plasma, serum or purified IgG from HIV-
infected individuals. These incubations were done in the presence
and absence of exogenous cytokines. NK cells responding to
ADCC antibodies were evaluated for IFNc production and
expression of the CD107a degranulation marker.
Methods and Materials
Study Population
We studied ADCC induced NK cell activation responses elicited
by sera samples from 32 HIV-infected subjects not on antire-
troviral therapy recruited through the Kirby Institute (Sydney,
Australia). Table 1 provides the demographics and clinical
characteristics of these patients. Plasma and sera samples from
an additional 19 HIV-infected individuals recruited from the
Melbourne Sexual Health Centre and one HIV-infected in-
dividual from La Clinique l’Actuel, Montreal, Quebec, Canada
were utilized to study envelope-specific ADCC responses. HIV-
uninfected healthy laboratory volunteers provided whole blood,
for assessment of NK cell function. All subjects provided informed
consent for participating in this study and human research and
ethics committees from all participating study sites approved this
study.
HLA Typing
Kits from Atria Genetics was used to conduct sequence-based
typing of HLA-B alleles. Otherwise, HLA-B typing was performed
by the Victorian Transplant and Immunogenetics Service
(Parkville, Australia), using sequence-based typing.
Anti-HIV ADCC NK Cell Activation Assay
As previously described [12], a whole blood assay was used to
assess NK cell activation by ADCC Abs. Briefly, 150 ml of HIV-
uninfected healthy control whole blood plus 50 ml of ADCC-
competent HIV-infected plasma/serum (stored at 220uC), or
purified IgG, was incubated at 37uC for 5 hours with 1 mg/ml of
HIV Env peptide pool or whole gp140 protein, Brefeldin A (5 mg/
ml, Sigma) and Monensin (6 mg/ml, Sigma). ADCC responses
were assessed using either a peptide pool containing 15-mers that
overlapped by 11 amino acids or whole gp140 protein. The
peptide pool spanned the HIV-1 consensus subtype B Env protein
(kindly supplied by the NIH AIDS Reagent Repository). As
previous described, the gp140 protein was obtained from
purification of the supernatant of HeLa or 293T cells transfected
with the gp140 gene from the subtype B AD8 isolate [31]. After
incubation, cells were surface stained with Per-CP-conjugated
anti-CD3, FITC-conjugated anti-CD2, PE-conjugated anti-
KIR3DL1, PE-Cy7-conjugated anti-CD56 and APC-conjugated
anti-CD107a (All from BD Biosciences). Next, whole blood was
treated with lysing solution (BD Biosciences) to remove red blood
cells, and the remaining white blood cells were treated with
permeabilization solution (BD Biosciences) and stained with
Alexa700-conjugated anti-IFNc antibody (BD Biosciences). Flow
cytometry data was collected using a FACS Canto II Flow
cytometer (BD Biosciences), and was analyzed using Flow Jo
Version 9.2 software (Tree Star). We have previously shown this
assay is not dependent on immune complexes activating NK cells
[30]. The assay works efficiently using either overlapping peptides
or whole Env protein as the HIV antigen.
IgG Purification and Depletion from Sera
To assess the impact of soluble serum/plasma factors on the
skewing of NK cell activation profiles, we purified total IgG from
serum over a protein G spin column (Thermo Fisher Scientific) to
use in the ADCC ICS assay [12]. Sera were bound to protein G
columns for 4 hours with end over end agitation before elution of
IgG as per the manufacturer’s instruction. Purified IgG samples
were then dialyzed in 2 ml mini dialysis tubes (GE Healthcare)
Table 1. Clinical characteristics of HIV-infected donors.
Mean (range)
Number 32
Age 41 (28–65)
Female/Male 1/31
CD4
+ cell count (cells/ml) 746.5 (504-1310)
Viral load (copies/ml) 290 (,50-203100)
doi:10.1371/journal.pone.0038580.t001
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filter devices (Millipore). IgG was also depleted from sera using
protein G spin columns (Thermo Fisher Scientific). IgG-depleted
sera was then combined with IgG from a single source and used in
the ADCC ISC assay described above, to assess the effect of
soluble sera factors on a known ADCC-mediated NK cell
activation response.
Anti-Env IgG ELISA
100 ng of HIV-1AD8 Env gp140 purified from media condi-
tioned by a stable gp140-expressing cell line (31) was absorbed
onto the bottom of ELISA plate wells in coating buffer (20 mM
Tris pH 8.8, 100 mM NaCl) overnight at 4uC. Wells were then
blocked with blocking buffer (5% skim milk powder in PBS/0.1%
Tween 20) for 1 hour. Patient samples were added as half log
dilution series in block buffer and incubated for 4 hours at room
temperature followed by washing with PBS/0.1% Tween 20. HRP
conjugated antibody against human IgG in blocking buffer was
then added and incubated for 1 hour. After washing ELISAs were
developed using standard techniques. Background was measured
by titration of HIV negative human sera. Wells were considered
positive when OD was at least 5-fold higher than background.
Endpoint titers (most dilute samples giving a positive reading) were
averaged over two assays.
Cytokines
In vitro supplementation with the following cytokines and growth
factors, for the five hour duration of the anti-HIV ADCC assay,
was studied to assess their influence on NK cell activation profiles:
IL-10 (50 ng/ml) (BD Biosciences), IL-15 (5 ng/ml) (R&D
Systems), IL-4 (50 Units/ml) (BD Biosciences), GM-CSF (1 mg/
ml) (BD Biosciences), IL-12 (100 ng/ml) (R&D Systems), IL-7
(50 ng/ml) (BD Biosciences), TNFa (200 ng/ml) (eBioscience) and
LPS (1 mg/ml) (Sigma).
Statistical Analyses
Data analyses were performed using GraphPad Prism Version
4.0 software. Data sets were tested for normal distribution using
the Kolmogorov-Smirnov test. Parametric data was analyzed
using T-tests or paired T-tests. Non-parametric data was
compared using Mann-Whitney tests, Wilcoxon Matched Pairs
tests, or Spearman correlations.
Results
Skewed ADCC-induced NK Cell Activation Profiles
Mediated by Sera from HIV-infected Individuals
NK cells exhibit a number of functions when activated by the Fc
portion of ADCC antibodies, including the expression of cytokines
and the degranulation and lysis of target cells. We hypothesized
that ADCC-induced NK cell effector functions may be differen-
tially regulated depending on the cytokine milieu of the plasma.
To evaluate this hypothesis we simultaneously evaluated sera
samples obtained from a cohort of 32 antiretroviral therapy naive
HIV-infected subjects for their ability to activate fresh NK cells in
blood obtained from a single healthy donor in the presence of Env
peptide or protein antigens. We utilized a previously described
flow cytometric assay of antibody-mediated NK cell activation
[12,15,29,30,32–34]. This simple assay studies the ability of donor
NK cells within whole blood to be activated by antibodies within
HIV
+ sera samples recognizing HIV peptides or Env proteins. The
NK cell activation in this assay occurs only when both peptides/
proteins and antibodies are present (Fig. 1a). Furthermore, this
assay is not dependent on NK cell recognition of immune
complexes.
We observed marked differences in the ability of NK cells from
the same donor to express IFNc, CD107a or both effector
molecules in response to the same HIV Env antigens using
different HIV
+ sera samples - examples are shown in Fig. 1b. We
quantified this difference by assessing whether there was markedly
greater IFNc expression, greater CD107a expression or similar
expression of both molecules from NK cells. Quantification was
performed by using a 1.5% differential to determine if responses
were skewed towards a particular response profile. As such,
responses that exhibited equal to or higher than 1.5% NK cell
expression of one effector molecule than the other were considered
skewed for that response, while responses with less than 1.5%
differences were considered equal. For stimulations involving
gp140 protein CD107a was the predominant effector molecule
expressed in 22% of samples, whereas in a minority (6% of
samples) IFNc expression predominated (Fig. 1c). Similarly, for
stimulations involving Env peptide stimulation CD107a was the
predominant effector molecule expressed for 35% of samples,
whereas in a minority (6% of samples) IFNc expression
predominated (Fig. 1c). It should be noted that plasma samples
that induce skewed responses appear to induce similarly skewed
responses regardless of the source of donor NK cells. We assessed
anti-HIV ADCC using a single plasma source on 20 HIV-
uninfected controls. We found that the same source of plasma
consistently induced a CD107a-skewed NK cell functional profile;
the mean ratio between percent of NK cells expressing CD107a
and percent of NK cells expressing IFNc was 3.0 (range 1.2–16.9)
across the 20 subjects.
Previous research has suggested that individual NK cells within
an organism obtain diverse functional potentials through ontolog-
ical processes, such as NK cell education. As such, we questioned if
the differential responses induced by different serum samples were
reflective of the activation of different arrays of functionally
competent NK cells. To answer this question we compared the
total percentage of activated NK cells present in individuals that
mediated ‘‘skewed’’ and ‘‘even’’ ADCC responses against HIV
gp140. This analysis demonstrated that skewed responses were
associated with higher percentages of activated NK cells (7.9+/
20.8 vs. 3.4+/20.6, p,0.01, Mann-Whitney test) (Fig. 1d). It
should be noted that a similar observation was made for ADCC
responses against HIV Env peptides (Data not shown).
Next, we evaluated if the differences in magnitude and
functional profiles of NK cell-mediated ADCC responses to
different plasmas could be explained by different levels of anti-
HIV IgG present in the sera, or if it was related to other soluble
sera factors. As such, an anti-Env IgG ELISA was utilized to assess
the levels of anti-Env IgG in 31/32 sera samples (Due to limited
sample availability). Figure 1E illustrates that no correlation was
observed between the level of sera anti-Env IgG and the
magnitude the anti-HIV ADCC response (r=0.2, p=0.2,
Spearman correlation). Figure 1F illustrates that no difference in
sera anti-Env IgG was observed between sera mediating ‘‘skewed’’
responses and those mediating ‘‘even’’ responses (p.0.05, Mann-
Whitney test). These observations suggest that plasma factors in
additional to Env-specific IgG levels are influencing the magnitude
and functional profile of NK cell-mediated anti-HIV ADCC
responses.
Previous research has demonstrated that soluble plasma factors,
such as cytokines, can alter the immune responsiveness of NK cells
[16]. To assess if plasma-derived factors were responsible for these
skewed ADCC responses, we next purified IgG from the sera of 10
HIV-infected subjects with predominantly CD107a expression
Cytokines and NK Cell-Mediated ADCC
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profiles of NK cells activated with purified IgG in comparison to
whole sera. Four representative samples from these experiments
are shown in figure 2A. Despite having no effect on the total
percentage of responding NK cells (p.0.05, Wilcoxon Matched
Pairs Test) (Fig. 2B), IgG purification was consistently observed to
alter the response towards a more IFNc
+ response profile (Fig. 2C).
This is illustrated by the shift from plasma induced responses that
consisted of 94% of activated NK cells expressing CD107a and
36% of activated NK cells producing IFNc to pure IgG induced
responses that consisted of 80% of activated NK cells expressing
CD107a and 63% of activated NK cells producing IFNc. There
was significantly increased synthesis of IFNc in ADCC mediated
by purified IgG compared to that mediated by sera (63+/23.3 vs.
36+/25.1, p=0.0001, paired T-test) and significantly decreased
expression of CD107a in ADCC mediated by purified IgG
compared to that mediated by sera (80+/22.9 vs. 94+/21.0,
p=0.001, paired T-test). These results suggest that soluble factors,
other than IgG, within sera, are affecting the cytokine expression/
degranulation profile of NK cells following ADCC activation.
Figure 1. Differential NK cell activation patterns by HIV-specific ADCC. The ability of NK cells to respond to anti-HIV ADCC antibodies was
assessed using a flow-based assay. (A) Stimulated cells were stained with fluorochrome conjugated antibodies against CD3, CD2, CD56, CD107a and
IFNc. After collection on a FACS II Canto, lymphocytes were gated upon and NK cells were identified as CD3
2CD2
+CD56
+. Cells within the NK cell
population were assessed for IFNc production and CD107a expression prior to and following activation. (B) Zebra plots depict examples of the
diverse anti-HIV ADCC responses obtained when NK cells from a common donor are stimulated with sera from different HIV-infected individuals in
the presence of Env peptides (top) or gp140 protein (bottom). The numbers in the quadrants represent the percentages of responding NK cells that
are mediating IFNc
+CD107a
2, IFNc
2CD107a
+ and IFNc
+CD107a
+ responses. (C) The pie chart on the left illustrates the frequency with which IFNc
dominant, CD107a dominant and even response profiles were observed, when sera samples from 32 HIV-infected individuals were used to stimulate
NK cells from a common donor in the presence of gp140 protein. The pie chart on the right depicts the same analysis for stimulation with Env
peptides. (D) The box and whiskers plot depicts the assessment of the relationship between the ability of different sera to induce diverse anti-HIV
ADCC functional profiles against HIV gp140 and the magnitude of the total ADCC response. The total percent of NK cell activation was compared
between sera that induced ‘‘even’’ or ‘‘skewed’’ ADCC responses, using a T-test. (E) The scatter plot illustrates the relationship between the levelso f
sera anti-HIV gp140 IgG and the percent of total NK cells, from a common donor, activated by the sera in the whole blood ADCC assay in the
presence of gp140. This correlation was assessed with the Spearman correlation. (F) The scatter plot depicts the assessment of the impact of the level
of sera-associated anti-HIV gp140 IgG on the functional profile induced by different sera, evaluated by a T-test.
doi:10.1371/journal.pone.0038580.g001
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higher IFNc and lower CD107a expression following IgG
purification was due to soluble factors present within the plasma,
we next performed a set of experiments that involved separately
adding IgG-depleted sera from 10 different HIV-infected donors
that exhibited CD107a dominant responses to the purified IgG
from a single donor. Four representative examples of these
experiments are depicted in figure 2D. Similar to the results
suggesting that ADCC responses induced by whole plasma are
characterized by higher CD107a expression and lower IFNc
synthesis than ADCC responses mediated by purified IgG, the
addition of IgG-depleted plasma from different donors to
a common source of purified IgG increased the responding NK
cells that expressed CD107a and decreased the responding NK
cells that produced IFNc (Fig. 2E). Cumulatively, these results
demonstrate that soluble factors other than IgG, which are present
within the plasma/sera of HIV-infected individuals, influence the
functional profile of NK cells mediating anti-HIV ADCC.
Influence of Cytokines on HIV-specific ADCC Activation of
NK Cells
As our initial results suggested that soluble plasma factors have
an impact on NK cell-mediated effector functions, we selected
a series of soluble factors to assess their influence on the anti-HIV
ADCC induced activation profiles of NK cells. As discussed in the
introduction, these factors were chosen due to their previously
observed relevance to HIV infection [18–27]. These factors were
added into a standard culture of healthy donor whole blood, Env
antigens and plasma from an HIV-infected donor with known
anti-Env ADCC antibodies. This experiment was repeated with
whole blood from four HIV-uninfected donors. We observed
consistent alterations in the profile of NK cell activation in the
presence of several cytokines (Figure 3). GM-CSF and IL-4 both
exhibited an inhibitory effect on overall Env-specific ADCC-
induced NK cell activation, decreasing responses in all donors
studied. IL-12, TNF-a and IL-7 had little overall effect on ADCC-
mediated NK cell activation in the donors. However, both IL-10
and IL-15 had a markedly positive effect on ADCC-induced NK
cell activation, increasing ADCC responses in all 4 donors. These
results suggest that cytokines can alter the immunological
microenvironment within which anti-HIV ADCC responses
occur, increasing or decreasing the potency of these anti-viral
responses.
Effects of IL-10 and IL-15 on Anti-HIV ADCC Induced NK
Cell Activation
As IL-10 and IL-15 both enhanced NK cell-mediated anti-HIV
ADCC effector functions, we performed a detailed assessment of
the influences of these cytokines on NK cell-mediated anti-HIV
ADCC. Since we observed an impact of these cytokines on the
ability of NK cells to both produce IFNc and express CD107a, we
first performed titrations to elucidate the concentrations at which
these cytokines are active (Figure 4A). These titrations also served
to confirm the consistency of the effect of IL-10 and IL-15 across
NK cells from several donors. While IL-10 required relatively high
levels (i.e., 25–50 ng/ml) to enhance anti-HIV ADCC induced
NK cell IFNc production and degranulation, IL-15 maximally
increased both NK cell effector functions at low concentrations
Figure 2. Effect of IgG purification on NK cell-mediated ADCC. The impact of non-IgG soluble sera factors was assessed by activating NK cells
for ADCC functionality in the presence of whole sera, purified IgG, or common purified IgG in the presence of IgG-depleted sera from a series of
donors. (A) Zebra plots depict the anti-HIV ADCC mediated by NK cells when incubated with whole sera or IgG purified from the same sera. The
values depicted represent the percentages of total NK cells mediating CD107a
+IFNc
2, CD107a
2IFNc
+, or CD107a
+IFNc
+ functional profiles. (B) The
scatter plot depicts a comparison of the percentage of total NK cells mediating ADCC-induced effector functions after stimulation of NK cells from
a common donor with sera or IgG purified from sera. This difference was assessed with a paired T-test. (C) The graph on the top illustrates the percent
of responding NK cells expressing CD107a after stimulation with sera or IgG purified from the same sera. The graph on the bottom illustrates the
percent of responding NK cells producing IFNc after stimulation with sera or IgG purified from the same sera. Differences were assessed with paired
T-tests. (D) Zebra plots depict the response of NK cells from a common donor to anti-HIV ADCC when incubated with purified IgG from a common
donor, sera from a series of donors, or purified IgG from a common donor combined with IgG-depleted sera from the series of donors. The values
depicted represent the percentages of responding NK cells mediating CD107a
+IFNc
2, CD107a
2IFNc
+, or CD107a
+IFNc
+ functional profiles. (E) The
graph illustrates the alteration of the NK cell-mediated ADCC functional profile induce by the common purified IgG after the addition of IgG-depleted
sera from a series of donors.
doi:10.1371/journal.pone.0038580.g002
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influence the effector functions of NK cells at concentrations that
could be achievable through therapeutic mechanisms.
Control of viral infections has been associated with simultaneous
mediation of several cell-based effector functions [35–37]. Indeed,
natural control of HIV-infection has been associated with
polyfunctional CTL and NK cell responses. As polyfunctional,
rather than monofunctional, NK cell-mediated responses would be
preferable to obtain by prophylactic and/or therapeutic interven-
tions, we next assessed the impact of exogenous cytokines on the
ability of NK cells to mediate more than one effector function
simultaneously. Since different plasmas contain different arrays of
biologically active cytokines that could influence the effects of
exogenous cytokines, we assessed if the effects of adding IL-10 and
IL-15 were consistent across a series of HIV-infected plasmas.
Regardless of the plasma used in the whole blood ICS assay, we
observed a consistent increase in the frequency of cells capable of
mediating bifunctional (IFNc
+CD107a
+) responses when IL-10
Figure 3. Effect of exogenous cytokines on ADCC-induced NK cell activation. A suite of 7 cytokines and LPS was added separately to a mix
of HIV
+ plasma co-incubated with healthy donor blood and HIV-1 Env antigens. Gated CD3
2CD2
+CD56
+ NK cells were studied for CD107a and IFNc
expression. These experiments were repeated using whole blood from four separate donors (A) Zebra plots depict the anti-HIV ADCC mediated by NK
cells when incubated with cytokines in the absence of anti-HIV antibodies and Env antigens, incubated with anti-HIV antibodies and Env antigens
with no cytokines added, or with the addition of cytokines. The values shown represent the percentages of total NK cells expressing both IFNc and
CD107a. (B) The effect of all cytokines and LPS on ADCC-driven NK cell activation is shown, expressed as a ratio of the response with cytokine added
to the response without cytokine. The effect of cytokine addition on both total CD107a
+ and total IFNc
+ responses is shown. Error bars represent
variation between different whole blood donors.
doi:10.1371/journal.pone.0038580.g003
Figure 4. Consistent effects of IL-10 and IL-15 across numerous donors. (A) Titration curves depict the effects of adding IL-10 or IL-15 to
donor NK cells from three donors, which were all stimulated with the same HIV
+ plasma in the presence of HIV-1 Env antigen. (B) NK cells from
a common donor were stimulated with plasma from 9 HIV-infected individuals in the presence of HIV-1 Env antigen, with or without exogenous
cytokines. Graphs on the top demonstrate the consistency of the effect of exogenous IL-10 and IL-15 on bifunctional (IFNc
+CD107a
+) response
profiles, regardless of the source of the plasma. Graphs on the bottom depict the consistency of the effect of exogenous IL-10 (50 ng/ml) and IL-15
(5 ng/ml) on the percentage contribution bifunctional responses make to the total NK cell response.
doi:10.1371/journal.pone.0038580.g004
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(2.5+/20.8 vs. 4.9+/21.5, p,0.05, paired T-test) were added
(Figure 4B). Indeed, exogenous IL-10 (19.7+/23.2 vs. 24.8+/
23.4, p,0.01, paired T-test) and IL-15 (19.7+/23.2 vs. 32.0+/
23.9, p,0.01, paired T-test) increased the contribution that
bifunctional responses made to the total NK cell response
(Figure 4B). The observation that exogenous cytokines have
consistent effects across a series of HIV-infected plasmas suggests
that therapeutic use of exogenous cytokines would have a similar
effect across many HIV-infected individuals. Overall, these results
suggest that polyfunctional cellular responses, which have been
associated with natural protection from HIV disease progression
[1,35–37], are achievable through anti-HIV ADCC antibodies,
especially in the presence of exogenous cytokines.
Importance of NK Cell Education for Effects of Exogenous
Cytokines on NK Cell-mediated Anti-HIV ADCC
The ability of NK cells to mediate effector functions is
controlled by a developmental process known as education [28].
In short, this process ensures self-tolerance of NK cells by only
conferring functional potential upon NK cells that express
inhibitory receptors for self-ligands. Recent research suggests that
the stronger the inhibitory signal delivered to NK cells during this
process, the stronger and wider array of effector functions
mediated by the NK cell [38]. Indeed, polyfunctional NK cell
responses occur more frequently in NK cells that are educated by
KIR3DL1/HLA-Bw4 combinations that are protective against
HIV infection and/or disease progression [36,37]. Interestingly,
KIR3DL1
+ NK cells from HLA-Bw4 carriers have also been
demonstrated to mediate higher bifunctional anti-HIV ADCC
responses than the same NK cell subset from HLA-Bw6
homozygotes [15]. As we observed a greater effect of exogenous
cytokines on bifunctional NK cells, we next assessed if NK cells
educated through KIR3DL1/HLA-Bw4 interactions are more
sensitive than KIR3DL1
+ NK cells from HLA-Bw6 homozygotes
to exogenous cytokine treatment. Figure 5a illustrates the gating
strategy we employed to distinguish KIR3DL1
+/2 NK cells. Since
exogenous IL-15 induced the largest increase in bifunctional
ADCC responses, we assessed the role of educated NK cells in
exogenous cytokine enhanced functionality using IL-15. We
assessed groups of 9 HLA-Bw4
+ individuals and 5 HLA-Bw6
homozygous donors and found that exogenous IL-15 treatment
significantly increased the bifunctional activity of KIR3DL1
+ NK
cells from HLA-Bw4 carriers (4.5+/21.1 vs. 13.3+/23.2, p,0.01,
paired T-test), but not from HLA-Bw6 homozygotes (1.98+/20.8
vs. 6.4+/22.8, p.0.05, paired T-test) (Figure 5B). Although
increases in bifunctional activity were consistently observed HLA-
Bw6 homozygotes, the reason these changes did not reach
significance could reflect the lower responsiveness of non-educated
NK cells to cytokine stimulation [14,39].
Discussion
Several studies have linked NK cell-mediated anti-HIV ADCC
to protection against HIV infection and/or disease progression [6–
10]. Although several assays exist to evaluate anti-HIV ADCC, the
readouts of these experimental systems are influenced by several
factors that could confound associations of ADCC with HIV
disease progression. Most assays measuring anti-HIV ADCC
analyze plasma or sera from HIV-infected individuals. As HIV
infection is associated with immune activation and perturbations
of plasma cytokine levels [16], these samples often contain a suite
of biologically active factors that can skew the ADCC measure-
ment. Indeed, using a NK cell activation anti-HIV ADCC assay
we observed that, depending on the source of serum used, NK
cells from a common donor mediated a series of responses either
skewed towards cytokine production, degranulation or equally
spread across both effector functions. These skewed responses
were dependent upon soluble plasma/sera factors and not solely
due to intrinsic qualities of anti-HIV antibodies, as purification of
IgG was associated with alteration of NK cell effector functions.
Exogenous addition of IL-10 or IL-15 markedly increased NK
cell-mediated anti-HIV ADCC effector functions. The effects of
IL-15 were observed most potently on NK cells educated through
co-expression of KIR3DL1 and HLA-Bw4, which have previously
been associated with protection against HIV infection and/or
disease progression [40,41]. Of the molecules tested, IL-4 and
GM-CSF had a negative influence on NK cell activation, and IL-4
has been implicated in HIV pathogenesis [18]. Surprisingly, no
effect was observed for IL-12 on anti-HIV ADCC. This could
reflect differences in the methodology utilized in the current
manuscript compared to other investigations. For example, the
current investigation added IL-12 to the NK cells for a brief five
hour period. Other investigators generally add IL-12 to the NK
cells for an overnight period prior to NK cell functional assays
[42].
The effects of cytokines on NK cell-mediated anti-HIV ADCC
effector functions are potently observed within the KIR3DL1
educated NK cell subset mediating both IFNc production and
degranulation as assessed by CD107a expression. As educated NK
cells mediating polyfunctionality have been associated with
protection from HIV infection and/or disease progression
[36,37], the ability of cytokines to alter the functionality of these
NK cells may partially explain the association of certain cytokine
perturbations with protection from HIV infection or advancement
of HIV disease. Indeed, the functional observations of this study
suggest this possibility. We observed that IL-10 and IL-15
enhanced NK cell functionality. Previous research has demon-
strated that both IL-10 and IL-15 can enhance NK cell functions,
including ADCC [14,43–48]. The current investigation, however,
has built upon these previous studies by investigating the role for
IL-15 in a novel assay, as well as the ability of this cytokine to
improve upon the functions of ‘‘educated’’ and ‘‘uneducated’’ NK
cells. Interestingly, IL-15 has been demonstrated to be increased in
the breast milk that is fed to exposed uninfected infants [49].
Meanwhile, exposed-uninfected individuals and slow progressing
individuals have been demonstrated to carry IL-10 promoter
polymorphisms that result in high levels of plasma IL-10 [50,51].
Although IL-10 and IL-15 could act through multiple mechanisms
to assist in control of HIV, we speculate that an important
mechanism could be their ability to enhance NK cell responsive-
ness to ADCC antibodies. Future studies should evaluate the
association of overlap between NK cell education and plasma
cytokine levels with protection from HIV infection.
The observation that IL-10 and IL-15 can enhance anti-HIV
NK cell activity suggests that these cytokines may be potential
resources for prophylactic and/or therapeutic interventions.
Although the concentrations of exogenous cytokines that are
required to observe increases in NK cell functionality are above
what is observed in vivo [52], it is worth noting that long-term
changes in in vivo concentrations of cytokines could still be
mediating the skewed responses mediated by several plasma
samples. Previous research has demonstrated that the effects of
cytokines are synergistic [53]. Furthermore, neutralization of
plasma cytokines has been demonstrated to rescue NK cells from
the effects of inhibitory endogenous cytokines, such as TGF-b [54].
Lastly, although the high concentrations of exogenous cytokines
required to observe NK cell activation may not reflect in vivo
Cytokines and NK Cell-Mediated ADCC
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preventative or therapeutic interventions. The levels of IL-15
required to activate NK cells to mediate anti-HIV ADCC are
particularly intriguing, as it may be feasible to therapeutically
administer similar levels of IL-15 to HIV-infected individuals [55].
Although, the levels of exogenous IL-10 required to stimulate
increased anti-HIV ADCC are much higher, they too could likely
be supplied safely from an exogenous source [56]. The fact that
IL-10 enhances NK cell-mediated anti-HIV ADCC, however,
makes it a particularly attractive target. Although some previous
research has associated IL-10 with poor viral control, this is mostly
due the detrimental effects of IL-10 on CTL [19]. Future research
should investigate IL-10 as a component of an antibody containing
anti-HIV microbicide that utilizes the ADCC effector function of
NK cells. Our results, in combination with previous demonstra-
tions of high-producing IL-10 promoter polymorphisms in
exposed uninfected individuals [50], suggest that IL-10 may be
particularly well-suited to protect against HIV infection.
Demonstrating that exogenous cytokines can enhance NK cell-
mediated anti-HIV ADCC responses that have been associated
with protection from HIV infection and/or disease progression is
an important step towards understanding how to design better
ADCC-based therapeutics or vaccines. Our data suggests vaccines
co-expressing IL-15 [57] could result in strongly enhanced ADCC
potency. While this study investigated the effect of exogenous
cytokines on a small number of NK cell effector functions, future
research should elucidate the effector functions involved in viral
suppression/control and evaluate the effects of exogenous cytokine
stimulation on these functions. Additionally, analysis of mono-
clonal ADCC antibodies could also evaluate the influence of Fc
region glycosylation patterns on NK cell activation. With a broader
understanding of the factors determining the potency of anti-HIV
ADCC responses, such as NK cell education, antibody specificity
and soluble plasma factors, enhanced ADCC-based therapies and
vaccines can be more rationally designed.
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